Subscribe
19 November 2019GenericsRory O'Neill

Russian government approves compulsory drug licensing bill

The Russian government has endorsed legislation that would allow it to employ compulsory drug licensing in emergencies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
UK Labour promises public generics company, compulsory drug licensing
25 September 2019   Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Europe
UK Labour promises public generics company, compulsory drug licensing
25 September 2019   Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.

More on this story

Europe
UK Labour promises public generics company, compulsory drug licensing
25 September 2019   Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott